First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients - A phase II study

被引:26
作者
Daniele, B
Rosati, G
Tambaro, R
Ottaiano, A
De Maio, E
Pignata, S
Iaffaioli, RV
Rossi, A
Manzione, L
Gallo, C
Perrone, F
机构
[1] Natl Canc Inst, Clin Trials Off, I-80131 Naples, Italy
[2] Univ Naples 2, Naples, Italy
关键词
colorectal cancer; chemotherapy; elderly patients;
D O I
10.1097/00004836-200303000-00009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Colorectal cancer is one of the most common cancers in the elderly. Information on tolerability and efficacy of 5-Fluorouracil-based chemotherapy in such patients is limited. Primary aim of the study was to describe tolerability and activity of chemotherapy with the "de Gramont" schedule (FU bolus [400 mg/m(2)] + FU continuous infusion [600 mg/m2] + folinic acid [100 mg/m(2)] on days 1 and 2, every 2 weeks), in patients with advanced colorectal cancer aged 70 or older. Patients and methods: Patients aged 70 or more, with stage IV colorectal cancer, ECOG performance status not worse than 2. Results: Thirty-four patients were treated at two participating centers. Seven (20.6%, 95% exact CI = 8.7-37.9) had an objective response, complete in 3 and partial in 4 patients. Five cases of unacceptable toxicity were registered (2 cardiac, 1 each for liver, anemia and diarrhea). Fitting the statistical model to the observed data indicated that the treatment was sufficiently active and tolerated. Conclusions: The de Gramont scheme is active and tolerated in elderly patients with advanced colorectal cancer.
引用
收藏
页码:228 / 233
页数:6
相关论文
共 39 条
[11]   Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].
Douillard, JY ;
Cunningham, D ;
Roth, AD ;
Navarro, M ;
James, RD ;
Karasek, P ;
Jandik, P ;
Iveson, T ;
Carmichael, J ;
Alakl, M ;
Gruia, G ;
Awad, L ;
Rougier, P .
LANCET, 2000, 355 (9209) :1041-1047
[12]   ORAL DOXIFLURIDINE IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL-CANCER - A MULTICENTER PHASE-II STUDY [J].
FALCONE, A ;
PFANNER, E ;
RICCI, S ;
BERTUCCELLI, M ;
CIANCI, C ;
CARRAI, M ;
DEMARCO, S ;
CERIBELLI, A ;
BARDUAGNI, M ;
CALABRESI, F ;
COMELLA, G ;
SARCINA, R ;
LORUSSO, V ;
STAMPINO, CG ;
PANDOLFI, A ;
BRUZZI, P ;
CONTE, PF .
ANNALS OF ONCOLOGY, 1994, 5 (08) :760-762
[13]  
Feliu J, 1997, CANCER-AM CANCER SOC, V79, P1884, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1884::AID-CNCR7>3.0.CO
[14]  
2-G
[15]   Survival of colorectal cancer patients in Europe during the period 1978-1989 [J].
Gatta, G ;
Faivre, J ;
Capocaccia, R ;
de Leon, AP .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (14) :2176-2183
[16]   Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer [J].
Giacchetti, S ;
Perpoint, B ;
Zidani, R ;
Le Bail, N ;
Faggiuolo, R ;
Focan, C ;
Chollet, P ;
Llory, JF ;
Letourneau, Y ;
Coudert, B ;
Bertheaut-Cvitkovic, F ;
Larregain-Fournier, D ;
Le Rol, A ;
Walter, S ;
Adam, R ;
Misset, JL ;
Lévi, F .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :136-147
[17]   Underrepresentation of patients 65 years of age or older in cancer-treatment trials. [J].
Hutchins, LF ;
Unger, JM ;
Crowley, JJ ;
Coltman, CA ;
Albain, KS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (27) :2061-2067
[19]   Chemotherapy in elderly patients with colorectal cancer [J].
Köhne, CH ;
Grothey, A ;
Bokemeyer, C ;
Bontke, N ;
Aapro, M .
ANNALS OF ONCOLOGY, 2001, 12 (04) :435-442
[20]   ASSESSMENT OF OLDER PEOPLE - SELF-MAINTAINING AND INSTRUMENTAL ACTIVITIES OF DAILY LIVING [J].
LAWTON, MP ;
BRODY, EM .
GERONTOLOGIST, 1969, 9 (3P1) :179-&